ANDA 60677, held by GlaxoSmithKline. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 60677 (Totacillin-N), held by GlaxoSmithKline, was not approved, with 0 approved supplements and 0 published complete response letters.
| Totacillin-NEQ 125MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Totacillin-NEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Totacillin-NEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Totacillin-NEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Totacillin-NEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Totacillin-NEQ 10GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters